Close



Apr 2, 2024 07:00AM
Apr 1, 2024 07:02AM
Apr 1, 2024 07:00AM
Mar 14, 2024 07:00AM
Mar 12, 2024 07:03AM
Mar 12, 2024 07:00AM
Jan 22, 2024 07:02AM Autolus Therapeutics (AUTL) announces acceptance of BLA for obecabtagene autoleucel as potential treatment for r/r Adult B-cell ALL
Jan 22, 2024 07:00AM
Dec 22, 2023 07:00AM
Dec 22, 2023 07:00AM
Dec 11, 2023 03:59AM
Dec 9, 2023 08:30PM
Nov 27, 2023 07:01AM
Nov 27, 2023 07:00AM Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lym
Nov 27, 2023 07:00AM
Nov 15, 2023 07:00AM
Nov 2, 2023 09:00AM
Nov 2, 2023 07:11AM
Aug 3, 2023 07:00AM
Jun 2, 2023 07:00AM
Jun 2, 2023 07:00AM Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCO
May 4, 2023 07:00AM
Apr 27, 2023 07:00AM
Apr 27, 2023 07:00AM
Mar 7, 2023 07:00AM
Mar 7, 2023 07:00AM
Dec 8, 2022 04:03PM
Dec 8, 2022 04:02PM Autolus Therapeutics to Receive $70 Million in Milestone Payments from Blackstone Life Sciences
Dec 8, 2022 04:02PM
Dec 8, 2022 04:02PM
Dec 8, 2022 04:01PM
Dec 8, 2022 04:01PM
Nov 3, 2022 07:00AM
Nov 3, 2022 07:00AM
Aug 4, 2022 07:00AM Autolus Therapeutics Reports Second Quarter 2022 Financial Results and Operational Progress
Aug 4, 2022 07:00AM
Jun 15, 2022 07:00AM
May 5, 2022 07:00AM
May 5, 2022 07:00AM
Apr 25, 2022 07:01AM
Apr 25, 2022 07:01AM
Apr 25, 2022 07:01AM FDA Grants Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus’ CAR T cell therapy, obe-cel, for the treatment of adult B-ALL
Mar 31, 2022 07:03AM
Mar 31, 2022 07:00AM
Mar 31, 2022 07:00AM
Mar 3, 2022 07:00AM
Dec 30, 2021 11:32AM
Nov 8, 2021 05:41AM
Nov 8, 2021 02:00AM Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and advance broader platform
Nov 8, 2021 02:00AM

251,008 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All